• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 18, 2012

View Archived Issues

Economy Still No. 1 Topic as BIO Returns to Boston

BOSTON – When the Biotechnology Industry Organization's (BIO) annual international convention opened in Boston five years ago, the industry was basking in all its pre-recession glory, with plenty of money flowing into both new and existing ventures – some said too much – and one of the biggest concerns heading into the BIO meeting was whether lawmakers would quit locking horns and finally pass PDUFA IV. Read More

Valeant Pharmaceuticals Picks Up OraPharma for $426M

Valeant Pharmaceuticals Inc. continued its specialty pharma shopping spree with an agreement to acquire oral health firm OraPharma Inc. for $312 million with up to $114 million in additional milestones. Read More

Simple Animal Model Enables Embrace of Cancer Complexity

One of the disappointments of targeted cancer therapies has been that their promise of low toxicity has not been borne out. At the American Society of Clinical Oncology conference earlier this month, Geoffrey Shapiro of the Dana-Farber Cancer Institute told BioWorld Today that "alopecia" – hair loss – "and bone marrow toxicity have been replaced by diarrhea and rash" as the dose-limiting banes of therapeutic development. Read More

REMS Battle Could Heat Up PDUFA Reconciliation Talks

WASHINGTON – Reconciliation of the House and Senate versions of the PDUFA package could turn into a battle pitting brand drugmakers against generics as both sides fight for a little more market time. Read More

Compulsory Licensing: Much Ado or a Game-Changer?

The cost of doing biopharma business in Brazil, Russia, India and China, as well as other emerging and underdeveloped markets, could come with a significant trade-off if the budding compulsory licensing trend gains traction. And, at the moment, there's not much brand makers can do about it. Read More

Stock Movers

Read More

Financings Roundup

• Oxygen Biotherapeutics Inc., of Morrisville, N.C., said it entered agreements with institutional investors to amend the terms of its $7.5 million offering of registered shares of Series A convertible preferred stock and registered warrants to purchase shares. Read More

Other News To Note

• Questcor Pharmaceuticals Inc., of Anaheim, Calif., said its initial commercialization plans for rheumatology drug H.P. Acthar Gel (repository corticotropin injection) include the creation of a 12-member sales force, plus a national sales director and two regional sales managers. Read More

Clinic Roundup

• Kenta Biotech, of Zurich-Schlieren, Switzerland, reported that the first patient was enrolled in a Phase I/II trial with KBSA301, a fully human antibody for the treatment of severe pneumonia caused by S. aureus. The trial will involve 44 patients suffering from severe pneumonia caused by S. aureus admitted into intensive care units around Europe. They will receive a single dose of KBSA301, or placebo, in addition to standard antibiotic therapy. Read More

Pharma: Other News To Note

• Meda AB, of Goteborg, Sweden, reported that Edluar has received registration approval in Europe, via the decentralization process, to treat sleep disorders. National registration processes will follow in each country, with the first launches expected early next year. Read More

Pharma: Clinic Roundup

• Bristol-Myers Squibb Co., of New York, reported six-year follow-up results from a Phase III trial of Sprycel (dasatinib) in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia adult patients resistant or intolerant to Glivec (imatinib, Novartis AG), demonstrating a progression-free survival rate of 49.3 percent and an overall survival rate of 71 percent for patients receiving dasatinib, with 6 percent of patients progressing to accelerated or blast phase of the study at six years of follow-up. Read More

Bench Press - BioWorld Looks at Translational Medicine

International teams organized into the Human Microbiome Project published their initial surveys of the human microbiome last week. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe